When: Operating margin recovery above 20% in Q3 confirming acquisition accretion and synergy delivery

Then: Consider increasing to Overweight

When: Credible $9.84B deal synergy disclosure with 2027 organic growth guidance at mid-single-digit

Then: Consider increasing to Overweight

When: Daily close below $199.00 on >5M volume — multi-indicator regime change at 200 SMA/structural support break

Then: Downgrade to Underweight

When: Q3 EPS miss >5% with forward guidance cut to $8.00-$8.50 — synergy delivery thesis invalidated

Then: Downgrade to Underweight

When: MACD line crosses below zero AND closes below 50 SMA for 5+ consecutive sessions

Then: Initiate soft de-risking protocol

When: Sustained break below $185.00

Then: Full re-evaluation warranted

HOLD core position; do not initiate or add at $223; trim into rallies to $226-$230; add only on confirmed pullback to $210-$205 zone with stop below $200 (buffered to lower Bollinger band)

• Current price $223 with 24x forward P/E multiple; risk of compression to 20x equals 17% drawdown with unchanged fundamentals
• EPS estimate of $9.30 unconfirmed; acquisition synergies theoretical; margin recovery unproven in new macro regime
• Inventory up 31% quarter-over-quarter while revenue up ~5% year-over-year represents meaningful divergence
• Golden Cross occurring at upper Bollinger band with RSI at 68 and MACD extended from August peak indicates stretched technicals
• Binary Q3 earnings catalyst in six weeks; stock likely to reach $240 on beat or $200 on miss regardless of current action
• Polymarket signals 97% probability of no rate cuts in 2026, suggesting cost of capital headwinds persist
• ATR is $6 with stock moving 2.7% daily on average; stop at $199 too tight for position-trade framework, recommend $197-$200 buffer
• Adding at $223 with Q3 uncertainty creates 10% drawdown risk vs. waiting for $210 pullback to add at $195 on further weakness
• Year-over-year margin comparisons will be difficult as Q2 base included inflated pre-deal operating margins
• Integration noise can persist four quarters, not two, per historical patterns

→ vs aggressive: Golden Cross at upper Bollinger band with RSI at 68 and MACD extended is buying into maximum indicator stretch, not a fresh entry signal

→ vs aggressive: 28% rally from $175 occurred during Fed pivot trade when yields dipped; late innings of that move, not early innings

→ vs aggressive: Absence of pullback is not a reason to chase; it's a reason for caution when indicators are most extended

→ vs aggressive: Forward earnings estimate of $9.30 is built on untested assumptions post-Q2 acquisition close; premiums paid for unconfirmed earnings

→ vs aggressive: Q3 margin disappointment could re-rate 24x multiple to 28x quickly, causing stock decline regardless of technicals

HOLD with staged entry modifications; do not initiate at $223.77 today; next decision triggered by either confirmed breakout above $226.64 on volume above 7M shares or confirmed retest of $210-$205 zone on declining volume

• Rates risk is 'recognized but not yet fully discounted' — the 28% rally from May low happened amid biotech stabilization and defensive flows, not resolution of duration risk
• 24 times forward earnings is the right zone to be skeptical of; market is probably pricing $8.50 to $9.00 of forward earnings, not $9.30 best-case
• MACD at 3.29 is meaningfully below August peak of 5.5 — legitimate divergence concern the aggressive analyst glossed over
• 50 above 200 cross with 200 curling up is structurally meaningful regime change, not just tactical
• Inventory build of 31% QoQ against 5% YoY revenue growth is a 'yellow flag' warranting two quarters of monitoring, not action
• Margins compressed to 18% during integration with $4.6B goodwill added and $4.2B intangibles stepped up; should bottom 17-19% over next two prints
• Staged entry framework: 60% allocated to staged buy program, 30% deployed on breakout above $226.64 on volume above 7M shares, 30% on $210-$205 zone with two consecutive closes on declining volume
• Dynamic trailing stop at 10 EMA at $214.08 for new tranches; full exit only on close below 50 SMA at $205.09
• Q3 relief rally to $230-$240 possible on anticipation; trim 20-30% into strength and consider rotating to lower-correlation exposure as structural hedge

→ vs aggressive: The 'rates already priced in' thesis conflates offsetting factors with resolved risk; DHR rallied amid biotech stabilization and defensive flows, not rates easing

→ vs aggressive: MACD at 3.29 is still below August peak of 5.5 — this is a real divergence concern being explained away with moving goalposts

→ vs aggressive: The magnitude of multiple expansion is genuinely capped when 10-year is at 2007 highs and market pricing 97% probability of no cuts

→ vs aggressive: Waiting for confirmation before paying premium is wrong standard, but timing does matter for margin of safety; buying at 24x on modest beat could disappoint

→ vs conservative: Estimates are not worthless; markets price expectations and demanding certainty before paying premium leaves you buying at $240 after the move, not $210

→ vs conservative: Binary event framing underestimates marginal decision importance; entry multiple determines cushion going into the print

→ vs conservative: Overly bearish technical reading ignores that 50 above 200 cross with 200 curling up is structurally meaningful regime change

→ vs conservative: Both single breakout trigger at $227 and single pullback trigger at $210 are wrong shape; neither hedges against both scenarios simultaneously

→ vs conservative: Tightening stop to $200 or $197 should be framed as trailing stop on new tranches using dynamic support rather than hard exit